<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985266</url>
  </required_header>
  <id_info>
    <org_study_id>CCR5316</org_study_id>
    <nct_id>NCT04985266</nct_id>
  </id_info>
  <brief_title>A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer</brief_title>
  <acronym>TRAK-ER</acronym>
  <official_title>A Randomised Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Detection of molecular relapse with circulating tumour DNA analysis can identify which&#xD;
      patients with ER positive breast cancer are relapsing on adjuvant endocrine therapy. This&#xD;
      trial will aim to demonstrate that palbociclib and fulvestrant, can defer or prevent relapse&#xD;
      in patients with ctDNA detected molecular relapse.&#xD;
&#xD;
      The TRAK-ER trial will have two phases, a ctDNA surveillance phase and a randomised therapy&#xD;
      trial in patients with positive ctDNA.&#xD;
&#xD;
      The TRAK-ER trial will establish a ctDNA screening programme for patients with ER positive&#xD;
      breast cancer receiving adjuvant endocrine therapy with at least a further three years of&#xD;
      standard adjuvant endocrine therapy planned. Patients recruited into the TRAK-ER study will&#xD;
      have high-risk clinical features to identify patients at higher risk of future relapse.&#xD;
&#xD;
      ctDNA assays will be used to identify which people are at very high risk of relapse (i.e.&#xD;
      those with a positive ctDNA result), and randomise this high risk population between standard&#xD;
      endocrine therapy versus palbociclib plus fulvestrant for up to two years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TRAK-ER trial is a multi-centre, randomised, open-label trial in patients with early&#xD;
      stage oestrogen reception positive (ER+) human epidermal growth receptor-2 negative (HER2-)&#xD;
      breast cancer, whom have detectable circulating DNA (ctDNA) but no overt macroscopic disease&#xD;
      on imaging. TRAK-ER aims to demonstrate that fulvestrant plus palbociclib improves relapse&#xD;
      free survival compared to standard endocrine therapy in this patient group.&#xD;
&#xD;
      Despite current treatment, patients with ER+HER2- breast cancer are considered high-risk of&#xD;
      distant recurrence for more than the first two decades after initial diagnosis. ctDNA&#xD;
      analysis provides a non-invasive, serial source of tumour material which can monitor tumour&#xD;
      dynamics and detect molecular relapse.&#xD;
&#xD;
      TRAK-ER will be split into two phases, the first surveillance phase aims to investigate the&#xD;
      use of ctDNA to identify and predict the risk of molecular relapse in early ER+/HER2- breast&#xD;
      cancer patients whom are receiving adjuvant endocrine therapy with no overt macroscopic&#xD;
      disease on imaging. Using ctDNA assays, patients enrolled on TRAK-ER will receive ctDNA&#xD;
      testing on a three-monthly basis for up to three years. In the instance where ctDNA is&#xD;
      detected, imaging will determine whether overt disease is present. If a patient had a&#xD;
      positive ctDNA detection and no macroscopic disease on the staging scan, the patient will be&#xD;
      randomised to one of the treatment groups in the second phase of TRAK-ER, the treatment&#xD;
      phase.&#xD;
&#xD;
      The treatment phase of TRAK-ER will be a randomised, open-label study which aims to determine&#xD;
      whether fulvestrant plus palbociclib (intervention arm) improves relapse free survival&#xD;
      compared to standard endocrine therapy (control arm) in patients carried through from the&#xD;
      surveillance phase. Patients on each arm will receive treatment (fulvestrant plus palbociclib&#xD;
      or standard endocrine therapy) for up to 24 months. Six monthly imaging will determine the&#xD;
      presence of macroscopic disease. If macroscopic disease is observed, the patient will&#xD;
      discontinue TRAK-ER treatment and commence standard therapy outside of the TRAK-ER trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of positive ctDNA result during surveillance (Surveillance phase)</measure>
    <time_frame>Up to 36 months from entry to study</time_frame>
    <description>Test during the surveillance phase detects presence of ctDNA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of positive ctDNA result at first test (Surveillance phase)</measure>
    <time_frame>Start of study</time_frame>
    <description>Test during the surveillance phase detects presence of ctDNA in the first test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relapse free survival (Treatment phase)</measure>
    <time_frame>60 months from randomisation</time_frame>
    <description>Time from randomization to invasive local/regional recurrence (including ipsilateral invasive breast recurrence) or distant recurrence or death from any cause. Patients with second primary invasive cancers (breast or non-breast) would be censored at time of detection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of adverse events</measure>
    <time_frame>up to 24 months from randomisation</time_frame>
    <description>Frequency and severity of Adverse Events (AEs) assessed as per CTCAE v5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 60 months from randomisation</time_frame>
    <description>Time from randomisation to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive disease free survival</measure>
    <time_frame>up to 60 months from randomisation</time_frame>
    <description>Time from randomisation to invasive local/regional recurrence (including ipsilateral invasive breast recurrence), new breast cancer (ipsilateral or contralateral) or distant recurrence or death from any cause. Patients with non-invasive recurrences or second primary invasive cancers (non-breast) would be censored at time of detection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant recurrence free survival</measure>
    <time_frame>up to 60 months from randomisation</time_frame>
    <description>Time from randomization to distant invasive breast cancer recurrence or death from any cause. Patients with new contralateral invasive breast cancers or second primary invasive non-breast cancers would be censored at time of detection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L quality of life assessment: Mobility element</measure>
    <time_frame>up to 24 months from randomisation</time_frame>
    <description>Assessed using the 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L quality of life assessment: Self-care element</measure>
    <time_frame>up to 24 months from randomisation</time_frame>
    <description>Assessed using the 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L quality of life assessment: Usual activities element</measure>
    <time_frame>up to 24 months from randomisation</time_frame>
    <description>Assessed using the 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L quality of life assessment: Pain/ Discomfort element</measure>
    <time_frame>up to 24 months from randomisation</time_frame>
    <description>Assessed using the 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L quality of life assessment: Anxiety/ Depression element</measure>
    <time_frame>up to 24 months from randomisation</time_frame>
    <description>Assessed using the 5-point scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L quality of life assessment: Visual Analogue Scale</measure>
    <time_frame>up to 24 months from randomisation</time_frame>
    <description>Assessed using 0-100 scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>ER+ Breast Cancer</condition>
  <condition>HER2-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Standard endocrine therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard endocrine therapy will continue for up to 24 months on trial.&#xD;
Standard endocrine therapies include tamoxifen, and aromatase inhibitors (letrozole, anastrazole, exemestane).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Palbociclib and fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with palbociclib plus fulvestrant will continue for a maximum of 24 months.&#xD;
Palbociclib will be given orally once a day on days 1-21 of each 28 day cycle.&#xD;
Fulvestrant 500 mg will be administered on cycle 1 days 1 and 15, cycle 2 day 1 and then every 28 days thereafter (plus or minus 3 days) as two intramuscular injections of 250mg fulvestrant at each visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib 125Mg Tab</intervention_name>
    <description>Palbociclib Tablets, 125 mg orally once daily, beginning on Cycle 1, on Days 1-21 of each 28-day cycle.</description>
    <arm_group_label>Palbociclib and fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant injection</intervention_name>
    <description>Fulvestrant Intramuscular injections, 500 mg as two injection of 250mg fulvestrant in 5ml solution at each visit. No fulvestrant dose reductions are permitted. Administered on days 1, 15 (plus or minus 3 days), 29 (plus or minus 3 days), and every 28 (plus or minus 3 days) days thereafter.</description>
    <arm_group_label>Palbociclib and fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>As per clinical guidelines</description>
    <arm_group_label>Standard endocrine therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>As per clinical guidelines</description>
    <arm_group_label>Standard endocrine therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>As per clinical guidelines</description>
    <arm_group_label>Standard endocrine therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>As per clinical guidelines</description>
    <arm_group_label>Standard endocrine therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for ctDNA Surveillance:&#xD;
&#xD;
          1. Written informed consent to participate in the trial and to donation of tissue and&#xD;
             blood samples&#xD;
&#xD;
          2. Male or female patients aged 18 years or older&#xD;
&#xD;
          3. ECOG performance status 0, 1 or 2 (see&#xD;
             https://ecog-acrin.org/resources/ecog-performance-status)&#xD;
&#xD;
          4. Histologically proven primary ER+ (Allred score 6/8 or greater, or stain in ≥10% of&#xD;
             cancer cells) and HER2- (immunohistochemistry 0/1+ and/or negative by in situ&#xD;
             hybridization) breast cancer as determined by local laboratory&#xD;
&#xD;
          5. Patients with high risk early stage breast cancer according to at least one of the&#xD;
             following criteria:&#xD;
&#xD;
             Primary surgery (no other treatment prior to surgery) A. Four or more involved&#xD;
             axillary lymph nodes or positive supraclavicular lymph node at diagnosis, or&#xD;
&#xD;
             B. Tumour size &gt; 5 cm, regardless of lymph node status, or&#xD;
&#xD;
             C. 1-3 involved axillary lymph nodes and at least one of the following; i) Tumour size&#xD;
             &gt; 3 cm, ii) histological grade 3 iii) high genomic risk defined as Oncotype Dx&#xD;
             Recurrence Score &gt;=26, Prosigna score &gt;=60, EPclin risk score &gt;=4.0, or Mammaprint&#xD;
             high risk category, or&#xD;
&#xD;
             D. At least a 15% predicted residual risk of death within 10 years using NHS PREDICT&#xD;
             (see appendix A3 on calculating predicted residual risk of death with PREDICT)&#xD;
&#xD;
             Neoadjuvant chemotherapy (chemotherapy prior to surgery) E. At least one lymph node&#xD;
             positive (micrometastasis or macrometastasis) after chemotherapy F. Lymph node&#xD;
             negative and tumour size &gt; 3 cm after chemotherapy&#xD;
&#xD;
             Neoadjuvant endocrine therapy (endocrine based therapy prior to surgery) Use the&#xD;
             primary surgery criteria - staging tumour size and lymph node status may be either the&#xD;
             pathological staging after endocrine therapy or on the initial clinical staging prior&#xD;
             to neoadjuvant therapy&#xD;
&#xD;
          6. Available tissue from one archival tumour tissue sample (either from diagnostic&#xD;
             biopsy, primary surgery or where available residual disease post-neoadjuvant&#xD;
             chemotherapy)&#xD;
&#xD;
             i) Patients with bilateral tumours may enrol if both are ER+ and HER2- and if one&#xD;
             archival tissue sample can be provided from each tumour&#xD;
&#xD;
             ii) Patients with multifocal breast cancer whose histopathologically examined tumours&#xD;
             all meet pathologic criteria for ER+ and HER2- breast cancer, and two archival tissue&#xD;
             samples can be provided.&#xD;
&#xD;
          7. No evidence of macroscopic distant metastatic disease or incurable locally advanced&#xD;
             disease on staging scans conducted at any time since initial diagnosis.&#xD;
&#xD;
          8. Patients receiving standard endocrine therapy with aromatase inhibitors (letrozole,&#xD;
             anastrazole, exemestane), tamoxifen, or combination of such for a minimum of 6 months*&#xD;
             and maximum of 7 years duration with an additional three years of endocrine therapy&#xD;
             planned. Pre- or peri-menopausal patients may also receive GnRH analogues.&#xD;
&#xD;
             * patients may enrol during the first 6 months of standard endocrine therapy, and wait&#xD;
             until at least 6 months of endocrine therapy has been received prior to starting ctDNA&#xD;
             surveillance&#xD;
&#xD;
          9. Patients must have had surgery achieving clear margins (as per local guidelines)&#xD;
&#xD;
         10. Female and male patients of reproductive potential must be willing to use an adequate&#xD;
             method of contraception for the first three years of the trial, if randomised to&#xD;
             standard endocrine therapy for the duration of trial treatment through to at least 4&#xD;
             weeks after the last dose of trial treatment, and if randomised to fulvestrant and&#xD;
             palbociclib to 2 years after the last dose of fulvestrant (see section 4.6). Note:&#xD;
             Abstinence is acceptable if this is the usual lifestyle and preferred contraception&#xD;
             for the patient.&#xD;
&#xD;
         11. Patients willing to have frequent blood tests.&#xD;
&#xD;
        Inclusion Criteria for Interventional phase:&#xD;
&#xD;
          1. Signed informed consent for treatment&#xD;
&#xD;
          2. ECOG performance status 0, 1 or 2&#xD;
&#xD;
          3. Women of childbearing potential should have a negative urine or serum pregnancy test&#xD;
             within 72 hours prior to receiving the first dose of treatment. If the urine test is&#xD;
             positive or cannot be confirmed as negative, a serum pregnancy test will be required.&#xD;
             If the urine test is positive or cannot be confirmed as negative, a serum pregnancy&#xD;
             test will be required&#xD;
&#xD;
          4. Female and male patients of childbearing potential must be willing to use an adequate&#xD;
             method of contraception (section 4.6), starting with the first dose of treatment&#xD;
             through 4 weeks after the last dose of treatment if randomised to standard endocrine&#xD;
             therapy and 2 years after the last dose of fulvestrant if randomised to fulvestrant&#xD;
             and palbociclib. Note: Abstinence is acceptable if this is the usual lifestyle and&#xD;
             preferred contraception for the patient. Female patients will be deemed not of&#xD;
             childbearing potential if they are postmenopausal or have had irreversible&#xD;
             sterilisation&#xD;
&#xD;
          5. Patient has adequate bone marrow and organ function as defined by the following&#xD;
             laboratory values:&#xD;
&#xD;
               1. Absolute Neutrophil Count (ANC) ≥ 1.5 × 109/L&#xD;
&#xD;
               2. Platelets ≥ 100 × 109/L&#xD;
&#xD;
               3. Haemoglobin ≥ 100 g/L&#xD;
&#xD;
               4. INR ≤1.5&#xD;
&#xD;
               5. Creatinine &lt;1.5 x ULN and creatinine clearance ≥30ml/min&#xD;
&#xD;
               6. Total bilirubin &lt; ULN except for patients with Gilbert's syndrome who may only be&#xD;
                  included if the total bilirubin is ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN.&#xD;
&#xD;
               7. Alanine aminotransferase (ALT) &lt; 2.5 x ULN&#xD;
&#xD;
               8. Aspartate aminotransferase (AST) &lt; 2.5 × ULN&#xD;
&#xD;
          6. Patients must be post-menopausal OR Pre- or peri-menopausal patients or men may be&#xD;
             enrolled if they have ovarian suppression with the GnRH analogue goserelin or similar&#xD;
             GnRH analogue. Patients must have commenced goserelin or an alternative GnRH analogue&#xD;
             at least 2 weeks prior to Cycle 1 Day 1 and continue throughout the study if&#xD;
             randomised to fulvestrant and palbociclib.&#xD;
&#xD;
        Post-menopausal female patients, as defined by at least one of the following:&#xD;
&#xD;
          -  Age ≥60 years;&#xD;
&#xD;
          -  Age &lt;60 years and cessation of regular menses for at least 12 consecutive months with&#xD;
             no alternative pathological or physiological cause, and serum estradiol and FSH levels&#xD;
             within the institutional laboratory's reference range for post-menopausal females;&#xD;
&#xD;
          -  Documented bilateral oophorectomy;&#xD;
&#xD;
        Exclusion Criteria for ctDNA Surveillance:&#xD;
&#xD;
          1. Any concurrent or planned treatment for the current diagnosis of breast cancer other&#xD;
             than adjuvant endocrine therapy or a bisphosphonate.&#xD;
&#xD;
          2. Patients with prior exposure to a CDK 4/6 inhibitor as part of standard of care may&#xD;
             enrol only after at least 12 months from completing CDK4/6 therapy.&#xD;
&#xD;
          3. Prior exposure to fulvestrant is not permitted.&#xD;
&#xD;
          4. Prior diagnosis of cancer including prior diagnosis of breast cancer in the previous 5&#xD;
             years, other than for non-melanoma carcinoma of the skin or cervical carcinoma in situ&#xD;
&#xD;
          5. Patients previously entered into a therapeutic trial where experimental therapy is&#xD;
             continued post-surgery. Patients who have entered a clinical trial of a CDK4/6&#xD;
             inhibitor in the adjuvant setting are not eligible. Patients who received a CDK4/6&#xD;
             inhibitor only before an operation, with no post-operative adjuvant use, are eligible.&#xD;
&#xD;
          6. Treatment with an unlicensed or investigational product within 4 weeks prior&#xD;
             registration to trial&#xD;
&#xD;
          7. Patient has not recovered to ≤ grade 1 (except alopecia or certain other toxicities,&#xD;
             which in the opinion of the Investigator should not exclude the patient) from related&#xD;
             side effects of any prior antineoplastic therapy, not including side-effects of&#xD;
             endocrine therapy&#xD;
&#xD;
          8. Patient with impairment of gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of oral medication (e.g. Crohn's disease,&#xD;
             ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome,&#xD;
             or small bowel resection)&#xD;
&#xD;
          9. Patient has any other concurrent severe and/or uncontrolled medical condition that&#xD;
             would, in the Investigator' opinion cause unacceptable safety risks, contraindicate&#xD;
             patient participation in the clinical trial or compromise compliance with the&#xD;
             protocol.&#xD;
&#xD;
         10. Clinically significant uncontrolled heart disease including any of the following:&#xD;
&#xD;
               1. History of myocardial infarction (MI), angina pectoris, symptomatic pericarditis,&#xD;
                  or coronary artery bypass graft (CABG) within 6 months prior to trial entry&#xD;
&#xD;
               2. Symptomatic congestive heart failure&#xD;
&#xD;
               3. Long QT syndrome or family history of idiopathic sudden death or congenital long&#xD;
                  QT syndrome.&#xD;
&#xD;
               4. Cardiac arrhythmia.&#xD;
&#xD;
         11. History of pneumonitis, interstitial lung disease or pulmonary fibrosis&#xD;
&#xD;
         12. Known history of Human Immunodeficiency Virus (HIV) (testing not required as part of&#xD;
             study screening)&#xD;
&#xD;
         13. Known active Hepatitis B or Hepatitis C (testing not required as part of study&#xD;
             screening)&#xD;
&#xD;
         14. Females who are known to be pregnant or breastfeeding&#xD;
&#xD;
         15. History of bleeding diathesis (i.e. disseminated intravascular coagulation, clotting&#xD;
             factor deficiency), other known abnormalities in coagulation or treatment with&#xD;
             anticoagulants. Low molecular weight heparin (LMWH), low dose aspirin or clopidogrel&#xD;
             are permitted.&#xD;
&#xD;
         16. Child-Pugh class C hepatic impairment or creatinine clearance &lt; 30ml/min.&#xD;
&#xD;
        Exclusion Criteria for Interventional phase:&#xD;
&#xD;
          1. Evidence of recurrent disease (metastatic or local, see section 6.6 for management of&#xD;
             patients with potentially curable local recurrences) on staging scans conducted since&#xD;
             positive ctDNA result&#xD;
&#xD;
          2. Known hypersensitivity to the excipients of palbociclib plus fulvestrant&#xD;
&#xD;
          3. Any anti-cancer treatment since enrolling in the TRAK-ER study other than hormonal&#xD;
             therapy or a bisphosphonate. Prior exposure to fulvestrant is not permitted.&#xD;
&#xD;
          4. Diagnosis of an alternative cancer since enrolment in the trial other than&#xD;
             non-melanoma cancer of the skin or cervical carcinoma in situ&#xD;
&#xD;
          5. Patient has had major surgery within 4 weeks prior to starting trial treatment or has&#xD;
             not recovered from major side effects of such procedure&#xD;
&#xD;
          6. Patient is currently receiving warfarin or other coumarin derived anti-coagulant, for&#xD;
             treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight&#xD;
             heparin (LMWH), rivoroxiban or fondaparinux is allowed&#xD;
&#xD;
          7. Patient has not recovered to ≤ grade 1 (except alopecia or certain other toxicities,&#xD;
             which in the opinion of the Investigator should not exclude the patient) from related&#xD;
             side effects of any prior antineoplastic therapy, not including side-effects of&#xD;
             endocrine therapy&#xD;
&#xD;
          8. Patient with impairment of gastrointestinal (GI) function or GI disease that may&#xD;
             significantly alter the absorption of oral medication (e.g. Crohn's disease,&#xD;
             ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome,&#xD;
             or small bowel resection)&#xD;
&#xD;
          9. Patient has any other concurrent severe and/or uncontrolled medical condition that&#xD;
             would, in the Investigator' opinion cause unacceptable safety risks, contraindicate&#xD;
             patient participation in the clinical trial or compromise compliance with the&#xD;
             protocol.&#xD;
&#xD;
         10. Clinically significant uncontrolled heart disease including any of the following:&#xD;
&#xD;
               1. History of myocardial infarction (MI), angina pectoris, symptomatic pericarditis,&#xD;
                  or coronary artery bypass graft (CABG) within 6 months prior to trial entry&#xD;
&#xD;
               2. Symptomatic congestive heart failure&#xD;
&#xD;
               3. Long QT syndrome or family history of idiopathic sudden death or congenital long&#xD;
                  QT syndrome.&#xD;
&#xD;
               4. Cardiac arrhythmia.&#xD;
&#xD;
         11. Patient is currently receiving any of the following substances and cannot be&#xD;
             discontinued 7 days prior to Cycle 1 Day 1:&#xD;
&#xD;
               -  Medications that are strong inducers or inhibitors of CYP3A4 (section 8.5.2)&#xD;
&#xD;
               -  Herbal preparations/medications, dietary supplements, fruits (e.g grapefruit,&#xD;
                  pomelos, starfruit, Seville oranges) and their juice&#xD;
&#xD;
         12. History of pneumonitis, interstitial lung disease or pulmonary fibrosis&#xD;
&#xD;
         13. Known history of HIV (testing not required as part of study screening)&#xD;
&#xD;
         14. Known active Hepatitis B or Hepatitis C (testing not required as part of study&#xD;
             screening)&#xD;
&#xD;
         15. Patient has a history of non-compliance to medical regimen&#xD;
&#xD;
         16. History of bleeding diathesis (i.e. disseminated intravascular coagulation, clotting&#xD;
             factor deficiency), other known abnormalities in coagulation or treatment with&#xD;
             anticoagulants. Low molecular weight heparin (LMWH), low dose aspirin or clopidogrel&#xD;
             are permitted.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Turner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Project Manager</last_name>
    <phone>020 7808 2887</phone>
    <email>trak-er@rmh.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Project Manager</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Project Manager</last_name>
      <phone>02078082887</phone>
      <email>trak-er@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Nicholas Turner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013 Mar 28;368(13):1199-209. doi: 10.1056/NEJMoa1213261. Epub 2013 Mar 13.</citation>
    <PMID>23484797</PMID>
  </reference>
  <reference>
    <citation>O'Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, André F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Huang Bartlett C, Turner NC. The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer Discov. 2018 Nov;8(11):1390-1403. doi: 10.1158/2159-8290.CD-18-0264. Epub 2018 Sep 11.</citation>
    <PMID>30206110</PMID>
  </reference>
  <reference>
    <citation>Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.</citation>
    <PMID>28445469</PMID>
  </reference>
  <reference>
    <citation>Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.</citation>
    <PMID>24553385</PMID>
  </reference>
  <reference>
    <citation>Garcia-Murillas I, Chopra N, Comino-Méndez I, Beaney M, Tovey H, Cutts RJ, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh-Crestani G, Barry P, Johnston SRD, Ring A, Bliss J, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith IE, Turner NC. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol. 2019 Oct 1;5(10):1473-1478. doi: 10.1001/jamaoncol.2019.1838. Erratum in: JAMA Oncol. 2020 Jan 1;6(1):162.</citation>
    <PMID>31369045</PMID>
  </reference>
  <reference>
    <citation>Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021.</citation>
    <PMID>26311728</PMID>
  </reference>
  <reference>
    <citation>Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1.</citation>
    <PMID>26030518</PMID>
  </reference>
  <reference>
    <citation>Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 Nov 17;375(20):1925-1936.</citation>
    <PMID>27959613</PMID>
  </reference>
  <reference>
    <citation>Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527. Epub 2018 Oct 20.</citation>
    <PMID>30345905</PMID>
  </reference>
  <reference>
    <citation>Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015 Feb;14(2):130-46. doi: 10.1038/nrd4504. Review.</citation>
    <PMID>25633797</PMID>
  </reference>
  <reference>
    <citation>Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010 Oct 20;28(30):4594-600. doi: 10.1200/JCO.2010.28.8415. Epub 2010 Sep 20. Erratum in: J Clin Oncol. 2011 Jun 1;29(16):2293.</citation>
    <PMID>20855825</PMID>
  </reference>
  <reference>
    <citation>Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014 Jan;106(1):djt337. doi: 10.1093/jnci/djt337. Epub 2013 Dec 7.</citation>
    <PMID>24317176</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

